Disease modifying activity of celecoxib on articular cartilage in osteoarthritis
Completed
- Conditions
- artroseosteoarthritis
- Registration Number
- NL-OMON30920
- Lead Sponsor
- Sint Franciscus Gasthuis
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 172
Inclusion Criteria
Patients with knee osteoarthritis, who are eligible for and on the waiting list for total knee replacement surgery. Patients will be treated at the Sint Franciscus Gasthuis Hospital in Rotterdam.
Exclusion Criteria
Patients who are eligible for a total knee replacement operation for other reasons than osteoarthritis.
Patients with an increased risk of gastro-intestinal bleeding.
Patients with an increased risk of cardio-vascular disease such as a history of cardio-vascular disease like myocardium infarct, heart failure, CVA and TIA; patients with untreated/insufficiently treated hypertension; patients with angina pectoris and patients on oral anticoagulants.
Patients with serious liver and/or kidney function impairment.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The primary outcome parameter is the difference in proteoglycan release of the<br /><br>OA cartilage under the influence of treatment. </p><br>
- Secondary Outcome Measures
Name Time Method <p>The secondary outcome parameters are changes in several biochemical and<br /><br>histochemical characteristics of the OA cartilage including proteoglycan<br /><br>synthesis rate, proteoglycan content, prostaglandin E2 (PGE2) production, and<br /><br>COX-1 and COX-2 expression of cartilage.<br /><br>The tertiary outcome measures are changes in synovial tissue due to treatment<br /><br>measured by biochemical and histochemical techniques, including IL-1 and TNFa<br /><br>production, COX expression, and protease activity.</p><br>